Holen Sie sich die Stockscreener-App
9.50
1.04%
-0.10
Handel nachbörslich:
9.50
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Retail Surge: Will Rallybio Corporation benefit from current market trendsNew Guidance & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Energy Moves: Can Rallybio Corporation generate free cash flowJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves - TipRanks
Geopolitics Watch: Whats the profit margin of Rallybio CorporationWeekly Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $40.00 - Defense World
Rallybio (RLYB) Expected to Announce Earnings on Thursday - MarketBeat
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharmaletter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Rallybio to acquire Candid Therapeutics - Yahoo Finance
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio - Wilson Sonsini
Rallybio and Candid Therapeutics To Merge - citybiz
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? - Finviz
Candid, in a reverse merger with RallyBio, to go public - BioPharma Dive
Rallybio to acquire Candid Therapeutics in $505M deal - Investing.com
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline - MedCity News
Rallybio: Merger forms a TCE therapeutics leader with $500M+ capital to advance autoimmune disease pipeline - TradingView
Rallybio: Merger forms a top TCE therapeutics company with $700M cash, advancing a broad autoimmune pipeline - TradingView
Candid scores Nasdaq listing via reverse merger Rallybio - Fierce Biotech
Rallybio to merge with San Diego biotech in deal backed by $505M in financing - Hartford Business Journal
Rallybio to Merge with Candid Therapeutics in All-Stock Deal - TipRanks
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders - The AI Journal
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - BioSpace
Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Merger: Rallybio (RLYB) to combine with Candid with $505.5M concurrent financing - Stock Titan
Rallybio to Merge With Candid Therapeutics; Candid Holders to Own ~57.6% of Combined Company - TradingView
Candid Therapeutics, Rallybio (NASDAQ: RLYB) in $505M cash-backed merger - Stock Titan
Candid to go public via reverse merger with Rallybio - Endpoints News
Nvidia and Coherent announce a strategic partnership to jointly develop advanced optical technologies, aiming to drive the scaled development of next-generation data center architectures. - Bitget
Rallybio Corporation and Candid Therapeutics announce merger agreement - marketscreener.com
Rallybio Corporation And Candid Therapeutics Announce Merger Agreement - TradingView
RLYB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
5AM Ventures revises Rallybio (RLYB) ownership and discloses stock sales - Stock Titan
Rallybio’s RLYB116 Clears Phase 1 Milestone, Sharpening Its Autoimmune Pipeline - TipRanks
Short Interest in Rallybio Corporation (NASDAQ:RLYB) Declines By 72.5% - Defense World
RLYB PE Ratio & Valuation, Is RLYB Overvalued - Intellectia AI
Rallybio's Strategic Pivot: Clinical Milestones and Financial Runway in Focus - AD HOC NEWS
Rallybio (RLYB) Price Target Increased by 700.00% to 8.16 - Nasdaq
Lieber, Rallybio CFO, sells $3992 in shares By Investing.com - Investing.com UK
Lieber, Rallybio CFO, sells $3992 in shares - Investing.com
Rallybio (RLYB) CFO gets 2,500-share award, sells 789 shares for taxes - Stock Titan
Rallybio (NASDAQ: RLYB) director granted options in lieu of cash - Stock Titan
What is Rallybio Corporation’s valuation compared to sector2025 Market Trends & Daily Volume Surge Signals - mfd.ru
Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Cision News
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor By Investing.com - Investing.com Canada
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor - Investing.com Australia
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - BioSpace
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):